ID29285A - PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS - Google Patents

PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS

Info

Publication number
ID29285A
ID29285A IDW20002551A ID20002551A ID29285A ID 29285 A ID29285 A ID 29285A ID W20002551 A IDW20002551 A ID W20002551A ID 20002551 A ID20002551 A ID 20002551A ID 29285 A ID29285 A ID 29285A
Authority
ID
Indonesia
Prior art keywords
ribavirin
ifn
peg
treatment
chronic hepatitis
Prior art date
Application number
IDW20002551A
Other languages
English (en)
Indonesian (id)
Inventor
Friederike Zahm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ID29285A publication Critical patent/ID29285A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IDW20002551A 1998-06-08 1999-05-29 PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS ID29285A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110433 1998-06-08

Publications (1)

Publication Number Publication Date
ID29285A true ID29285A (id) 2001-08-16

Family

ID=8232086

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002551A ID29285A (id) 1998-06-08 1999-05-29 PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS

Country Status (34)

Country Link
US (3) US20030053986A1 (pl)
EP (1) EP1087778B1 (pl)
JP (2) JP3839667B2 (pl)
KR (2) KR20050055053A (pl)
CN (1) CN1170543C (pl)
AR (1) AR019855A1 (pl)
AT (1) ATE307597T1 (pl)
AU (1) AU767131B2 (pl)
BR (1) BR9911076A (pl)
CA (1) CA2334267C (pl)
CL (1) CL2010000828A1 (pl)
CO (1) CO5050297A1 (pl)
CZ (1) CZ298681B6 (pl)
DE (1) DE69927971T2 (pl)
DK (1) DK1087778T3 (pl)
ES (1) ES2251196T3 (pl)
HR (1) HRP20000808A2 (pl)
HU (1) HU228218B1 (pl)
ID (1) ID29285A (pl)
IL (2) IL139786A0 (pl)
MA (1) MA26641A1 (pl)
MY (1) MY124091A (pl)
NO (1) NO325598B1 (pl)
NZ (1) NZ508249A (pl)
PE (1) PE20000560A1 (pl)
PL (1) PL192364B1 (pl)
RS (1) RS50144B (pl)
RU (1) RU2271217C2 (pl)
SA (1) SA99200208B1 (pl)
SI (1) SI1087778T1 (pl)
TR (1) TR200003635T2 (pl)
TW (1) TWI241913B (pl)
WO (1) WO1999064016A1 (pl)
ZA (1) ZA200006814B (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003635T2 (tr) * 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
ES2275711T3 (es) * 2000-08-07 2007-06-16 Sciclone Pharmaceuticals, Inc. Tratamiento de la hepatitis c con timosina, interferon y ribavirina.
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN104193791A (zh) 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
WO2004046331A2 (en) 2002-11-15 2004-06-03 Idenix (Cayman) Limited 2’-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
AU2003300434A1 (en) * 2002-12-23 2004-07-22 Idenix (Cayman) Limited Process for the production of 3'-nucleoside prodrugs
EP2345659A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
BRPI0512360A (pt) * 2004-06-23 2008-03-11 Idenix Cayman Ltd derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae
US8886272B2 (en) 2004-07-13 2014-11-11 Dexcom, Inc. Analyte sensor
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2769377T3 (es) 2004-09-14 2020-06-25 Gilead Pharmasset Llc Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
RU2008109649A (ru) * 2005-08-15 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ПЭГ-IFNα И РИБАВИРИН ДЛЯ ЛЕЧЕНИЯ ВИРУСА ГЕПАТИТА В
US9201979B2 (en) * 2005-09-14 2015-12-01 Millennial Media, Inc. Syndication of a behavioral profile associated with an availability condition using a monetization platform
JP5254033B2 (ja) * 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
WO2009156456A1 (en) 2008-06-24 2009-12-30 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
CN102159245B (zh) * 2008-09-17 2013-07-24 贝林格尔.英格海姆国际有限公司 Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
CN102695513A (zh) 2008-12-23 2012-09-26 吉利德制药有限责任公司 核苷氨基磷酸酯
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
CN106139123A (zh) 2009-08-05 2016-11-23 爱力根公司 脂质运载蛋白突变蛋白的控制释放制剂
AU2010313497B2 (en) 2009-10-30 2013-08-01 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
EP2510357B1 (en) 2009-12-07 2016-03-30 Pieris AG Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
TR201906295T4 (tr) 2010-06-08 2019-05-21 Astrazeneca Ab IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
WO2012065978A1 (en) 2010-11-15 2012-05-24 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2863410T3 (es) 2011-12-13 2021-10-11 Pieris Pharmaceuticals Gmbh Métodos para prevenir o tratar ciertos trastornos mediante la inhibición de la unión de IL-4 y/o IL-13 a sus respectivos receptores.
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
US20140039923A1 (en) * 2012-08-03 2014-02-06 AxelaCare Health Solutions, Inc. Computer program, method, and system for receiving and managing patient data gathered during patient treatments
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
BR112015021681A2 (pt) 2013-03-14 2017-11-14 Daiichi Sankyo Co Ltd proteínas de ligação para pcsk9
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
BR112016027024A2 (pt) 2014-05-22 2017-10-31 Pieris Pharmaceuticals Gmbh polipeptídeos de ligação específica e seus usos
AU2016212087B2 (en) 2015-01-28 2019-11-07 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
CA2976687A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
CA2980839C (en) 2015-05-04 2024-09-10 Pieris Pharmaceuticals Gmbh CD137 SPECIFIC PROTEINS
WO2016177802A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
RU2754466C2 (ru) 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
CA2982034A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
EP3322433B1 (en) 2015-07-15 2023-05-31 Pieris Pharmaceuticals GmbH Novel proteins specific for lag-3
WO2017091850A1 (en) 2015-11-30 2017-06-08 Pieris Australia Pty Ltd. Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3571219A1 (en) 2017-01-18 2019-11-27 Pieris Pharmaceuticals GmbH Lipocalin muteins with binding affinity for lag-3
US20210363257A1 (en) 2018-07-31 2021-11-25 Pieris Pharmaceuticals Gmbh Novel fusion protein specific for cd137 and pd-l1
BR112021016829A2 (pt) 2019-02-26 2021-10-19 Pieris Pharmaceuticals Gmbh Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar simultaneamente as vias de sinalização, de coestimular células t, de induzir uma resposta de linfócitos e de induzir o aumento da citólise, composição farmacêutica e método para prevenir, melhorar ou tratar cânceres
JP2023527908A (ja) 2020-06-05 2023-06-30 ピエリス ファーマシューティカルズ ゲーエムベーハー ４－１ｂｂをターゲティングする多量体免疫調節物質
JP2024515564A (ja) 2021-04-08 2024-04-10 ピエリス ファーマシューティカルズ ゲーエムベーハー 結合組織増殖因子（ｃｔｇｆ）に特異的な新規リポカリンムテイン
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
CA3268207A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228
WO2025175123A1 (en) 2024-02-16 2025-08-21 Seagen Inc. Methods of treating cancer using fusion proteins specific for cd137 and cd228

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) * 1987-06-06 1988-12-15 Basf Ag Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5238915A (en) * 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
AU691225B2 (en) * 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2329474C (en) * 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
TR200003635T2 (tr) * 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.

Also Published As

Publication number Publication date
DK1087778T3 (da) 2005-12-19
CZ298681B6 (cs) 2007-12-19
TR200003635T2 (tr) 2001-04-20
NZ508249A (en) 2003-02-28
PE20000560A1 (es) 2000-07-05
DE69927971T2 (de) 2006-07-27
CL2010000828A1 (es) 2011-02-11
IL139786A (en) 2007-10-31
HK1037981A1 (en) 2002-03-01
AU4503399A (en) 1999-12-30
US20050031589A1 (en) 2005-02-10
YU77000A (sh) 2003-08-29
BR9911076A (pt) 2001-02-20
MY124091A (en) 2006-06-30
CA2334267A1 (en) 1999-12-16
SI1087778T1 (sl) 2006-02-28
US20070196385A1 (en) 2007-08-23
CN1305382A (zh) 2001-07-25
CO5050297A1 (es) 2001-06-27
HRP20000808A2 (en) 2001-10-31
EP1087778B1 (en) 2005-10-26
ES2251196T3 (es) 2006-04-16
JP3839667B2 (ja) 2006-11-01
HUP0102033A3 (en) 2010-01-28
CA2334267C (en) 2009-02-17
DE69927971D1 (de) 2005-12-01
AR019855A1 (es) 2002-03-20
WO1999064016A1 (en) 1999-12-16
HU228218B1 (en) 2013-02-28
ATE307597T1 (de) 2005-11-15
AU767131B2 (en) 2003-10-30
PL192364B1 (pl) 2006-10-31
MA26641A1 (fr) 2004-12-20
TWI241913B (en) 2005-10-21
PL344794A1 (en) 2001-11-19
NO325598B1 (no) 2008-06-23
SA99200208B1 (ar) 2006-08-15
ZA200006814B (en) 2002-05-03
CN1170543C (zh) 2004-10-13
RU2271217C2 (ru) 2006-03-10
NO20006178D0 (no) 2000-12-05
EP1087778A1 (en) 2001-04-04
NO20006178L (no) 2000-12-05
JP2002517451A (ja) 2002-06-18
IL139786A0 (en) 2002-02-10
HUP0102033A2 (hu) 2001-10-28
KR20010052622A (ko) 2001-06-25
RS50144B (sr) 2009-03-25
JP2006160759A (ja) 2006-06-22
KR20050055053A (ko) 2005-06-10
CZ20004487A3 (en) 2001-06-13
US20030053986A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
ID29285A (id) PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS
DE69801970D1 (de) Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion
BR9608758A (pt) Uso de ribavirina e interferom alfa para o tratamento de hepatite c
ID23646A (id) Benda penyerap cairan tubuh sekali pakai
ID22957A (id) Senyawa dan penggunaannya
ID29591A (id) Senyawa-senyawa kuinolina dan kuinoksalina
ID24147A (id) Benda penyerap cairan tubuh sekali pakai
ID23575A (id) Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina
FI20070005L (fi) L-nukleosidejä hepatiitti-B-viruksen ja Epstein-Barr-viruksen hoitamiseksi
EE9900003A (et) Meetod ja seade anduri fikseerimiseks kehasiseses luumenis
PT1233973E (pt) Derivados de adenosina n6-heterociclicos 5'-tio-substituida agonistas parciais ou totais de a1
DE69927464D1 (de) Körperflüssigkeiten absorbierender Wegwerfartikel
ID22956A (id) Sintesa disulfida dan polisulfida organik
DE69930647D1 (de) Struktur-analoga von amin-basen und nucleosiden
ID21332A (id) Metode dan komposisi untuk pengobatan dan pencegahan hiperurikemia
ID26297A (id) Celana jenis celana pendek sekali pakai dan proses pembuatannya
PT1164996E (pt) Sistemas terapeuticos transdermicos com nicotina e adicao de cetonas monoterpenicas
UA25852C2 (uk) Пристрій для діяhhя hа потік плиhhого середовища
ID23258A (id) Penarik pemberian-menyilang dan metodenya
ID24910A (id) Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral
DE69918447D1 (de) Antivirale kombinationen von lamivudin und adefovir
ID28797A (id) Tioredoksin dan pemrosesan biji-bijian
NO20006444L (no) Referanseforbindelse for anvendelse i ananlyser av levosimendanporsjoner
ID18913A (id) Turunan turunan tienopiridin dan penggunaannya
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C